article thumbnail

This Protein May Protect Against Alzheimer’s, Scientists Say

AuroBlog - Aurous Healthcare Clinical Trials blog

In the search for a treatment for Alzheimer’s disease, researchers have zeroed in on a protein with protective effects. A new study reveals how cholesterol and inflammation in different types of human brain cells interact with a protein called ABCA7, which regulates how molecules pass through cell membranes.

Protein 223
article thumbnail

WHO grants emergency use listing to SK bioscience’s SKYCovione

Pharmaceutical Technology

SKYCovione is a self-assembled nanoparticle vaccine and the 12th Covid-19 vaccine to receive a EUL from the regulator. Developed using pharmaceutical company GSK’s pandemic adjuvant, the vaccine targets the receptor-binding domain of the SARS-CoV-2 spike protein.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

ARTHEx Biotech raises funds to advance DM1 therapy to clinical trial

Pharmaceutical Technology

ARTHEx Biotech will use the funds to advance an antimiR oligonucleotide, ATX-01, to a Phase I/IIa clinical trial in the second half of 2023. It has a dual mechanism of action that targets toxic dystrophia myotonica protein kinase and MBNL protein.

article thumbnail

European regulators begin rolling review of AZ’s COVID-19 vaccine

pharmaphorum

European regulators have started a first ‘rolling review’ of a COVID-19 vaccine, which is being developed by AstraZeneca in collaboration with the University of Oxford. In a separate announcement, AstraZeneca said that a trial of the vaccine has resumed in Japan after a safety scare in the UK.

article thumbnail

Mouse Study Reveals Unlikely Connection Between Menthol And Alzheimer’s

AuroBlog - Aurous Healthcare Clinical Trials blog

In particular, researchers noticed a reduction in the interleukin-1-beta (IL-1β) protein, which helps to regulate the body’s […] It seems the chemical compound can stop some of the damage done to the brain that’s usually associated with the disease.

Protein 198
article thumbnail

Federal Court of Appeal Upholds First Trial Judgment under New PM(NOC) Regulations

Pharma in Brief

The Federal Court of Appeal has upheld the first trial judgment under the new Patented Medicines (Notice of Compliance) Regulations. The Trial Judge’s conclusion was consistent with the views of the experts he preferred and the principles in the governing jurisprudence. Trial decision. Appeal decision. Skilled person.

article thumbnail

FDA accepts AstraZeneca’s NDA for breast cancer combination therapy

Pharmaceutical Technology

Capivasertib is an investigational oral therapy and a potent adenosine triphosphate (ATP)-competitive inhibitor of all three AKT [protein kinase B] isoforms (AKT1/2/3). The regulator will announce its decision during the fourth quarter of 2023. The submission of the NDA was based on the findings of the CAPItello-291 Phase III trial.

HR 245